View Main Condition: Leukemia
Tapan Kadia is an Oncologist and a Hematologist Oncology expert in Houston, Texas. Kadia has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Adult T-Cell Leukemia. He is also highly rated in 37 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Kadia is currently accepting new patients.
Elizabeth Raetz is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in New York, New York. Raetz has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Adult T-Cell Leukemia. She is also highly rated in 6 other conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Infantile Neutropenia, and Bone Marrow Transplant. Raetz is currently accepting new patients.
Atae Utsunomiya practices in Kagoshima, Japan. Utsunomiya is rated as an Elite expert by MediFind in the treatment of Adult T-Cell Leukemia. They are also highly rated in 9 other conditions, according to our data. Their top areas of expertise are Adult T-Cell Leukemia, Leukemia, HTLV-1 Associated Myelopathy, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant.
Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to pre...
Summary: BACKGROUND: Cluster of differentiation 25 (CD25) (p55, Tac or interleukin 2 receptor (IL2R) alpha) is strongly expressed in virtually 100% of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTLV-1) related malignancy responding poorly to chemotherapy. In ATL, the humanized anti-CD25 monoclonal antibody (Mab) daclizumab produced 13-14% resp...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center